Vaxcyte
Vaxcyte is dedicated to eliminating bacterial infections through the development of broad-spectrum vaccines, including VAX-24 and VAX-31, using advanced synthetic techniques like the XpressCF™ platform.
Company Overview
Vaxcyte is dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. The company uses advanced chemistry and modern synthetic techniques, including the XpressCF™ cell-free protein synthesis platform, to produce broad-spectrum vaccines. Vaxcyte's mission is to develop innovative vaccines to combat severe bacterial infections and improve public health.
VAX-24 Vaccine Development
Vaxcyte is developing VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate, which is currently the broadest-spectrum PCV in U.S. clinics. VAX-24 has been granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. The company has completed enrollment for a Phase 2 study to evaluate VAX-24's efficacy in preventing invasive pneumococcal disease in infants. Vaxcyte plans to announce the topline safety, tolerability, and immunogenicity data by the first quarter of 2025.
VAX-31 Vaccine Development
Another of Vaxcyte's key projects is VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The company has completed enrollment for the VAX-31 adult Phase 1/2 study and expects to release topline safety, tolerability, and immunogenicity data in the third quarter of 2024. Following this readout, Vaxcyte intends to advance either VAX-24 or VAX-31 to the adult Phase 3 program.
Pipeline and Research Initiatives
Vaxcyte is also developing a range of other vaccine candidates. These include VAX-A1, a prophylactic vaccine for Group A Strep; VAX-PG, a therapeutic vaccine aimed at slowing or stopping periodontitis progression; and VAX-GI, a prophylactic vaccine for Shigella. These initiatives are part of Vaxcyte's broader strategy to engineer complex vaccines using cutting-edge technology.
Financial Health
Vaxcyte completed a successful $862.5 million follow-on financing in February 2024. As of March 31, 2024, the company held $1.9 billion in cash, cash equivalents, and investments. For the three months ending March 31, 2024, Vaxcyte reported research and development expenses of $94.6 million, general and administrative expenses of $19.9 million, and a net loss of $95.0 million. Additionally, Vaxcyte incurred $15.3 million in capital and facility buildout expenditures related to the construction of their dedicated manufacturing suite at Lonza.